Advertisement

Tumor Biology

, Volume 35, Issue 12, pp 12525–12534 | Cite as

The genetic association between pri-miR-34b/c polymorphism (rs4938723 T > C) and susceptibility to cancers: evidence from published studies

  • Xiaowei Li
  • Liguang Wang
  • Jianyu Yu
  • Jun Xu
  • Jiajun Du
Research Article

Abstract

Recently, several molecular epidemiological studies have focused on the association between pri-miR-34b/c rs4938723 SNP and the susceptibility to different cancers. Due to the controversial rather than conclusive results, we performed this meta-analysis to assess more precise and comprehensive conclusion about the association. Data published until July 2014 were collected from PubMed, Embase, Web of Science, Chinese National Knowledge Infrastructure, Wanfang Data, Chinese BioMedical Literature Database, and VIP database of Chinese Journal. Ultimately, 13 articles with a total of 7,753 cases and 8,014 controls were considered eligible for inclusion. The odds ratio (OR) and its 95 % confidence interval (95%CI) were used to assess the strength of association. In the overall analysis, a significant association between pri-miR-34b/c rs4938723 polymorphism and increased cancer susceptibility was found in heterozygous model (TC vs. TT: OR = 1.148, 95%CI 1.034–1.275, P = 0.010) and dominant model (CC + TC vs. TT: OR =1.166, 95%CI 1.028–1.322, P = 0.017). In subgroup analysis of ethnicity, pri-miR-34b/c rs4938723 polymorphism was significantly associated with an increased cancer susceptibility for Asian population in heterozygous model (TC vs. TT: OR = 1.169, 95%CI 1.031–1.326, P = 0.015) and dominant model (CC + TC vs. TT: OR = 1.185, 95%CI 1.017–1.382, P = 0.030), whereas no significant association for Caucasian population was observed in any genetic models. Intriguingly, stratified analysis revealed opposite results that pri-miR-34b/c polymorphism contributed to susceptibility to hepatocellular carcinoma while reduced susceptibility to colorectal cancer and esophageal squamous cell cancer in Asians. Considering some limitation of our meta-analysis, future well-designed case-control studies with larger sample sizes are required to confirm our findings.

Keywords

Single nucleotide polymorphism Pri-miR-34b/c Cancer susceptibility Meta-analysis 

Notes

Acknowledgments

This research was supported (in part) by Shandong Provincial Natural Science Foundation of China (ZR2013HZ001) and National Natural Science Foundation of China (81301728). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.

Conflicts of interest

None

Supplementary material

13277_2014_2572_MOESM1_ESM.docx (19 kb)
Table S1 (DOCX 18 kb)
13277_2014_2572_MOESM2_ESM.docx (13 kb)
ESM 1 (DOCX 13 kb)

References

  1. 1.
    Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–5. Google Scholar
  2. 2.
    Babashah S, Soleimani M. The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. Eur J Cancer. 2011;47:1127–37.PubMedCrossRefGoogle Scholar
  3. 3.
    Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66.PubMedCrossRefGoogle Scholar
  4. 4.
    Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microrna targets. Cell. 2005;120:15–20.PubMedCrossRefGoogle Scholar
  5. 5.
    Saunders MA, Liang H, Li WH. Human polymorphism at micrornas and microrna target sites. Proc Natl Acad Sci U S A. 2007;104:3300–5.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    He B, Pan Y, Cho WC, Xu Y, Gu L, Nie Z, et al. The association between four genetic variants in micrornas (rs11614913, rs2910164, rs3746444, rs2292832) and cancer risk: evidence from published studies. PLoS One. 2012;7:e49032.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Wang F, Sun G, Zou Y, Li Y, Hao L, Pan F. Association of microrna-499 rs3746444 polymorphism with cancer risk: evidence from 7188 cases and 8548 controls. PLoS One. 2012;7:e45042.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Srivastava K, Srivastava A. Comprehensive review of genetic association studies and meta-analyses on mirna polymorphisms and cancer risk. PLoS One. 2012;7:e50966.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Qiu MT, Hu JW, Ding XX, Yang X, Zhang Z, Yin R, et al. Hsa-mir-499 rs3746444 polymorphism contributes to cancer risk: a meta-analysis of 12 studies. PLoS One. 2012;7:e50887.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Li L, Wu J, Sima X, Bai P, Deng W, Deng X, et al. Interactions of mir-34b/c and tp-53 polymorphisms on the risk of nasopharyngeal carcinoma. Tumour Biol J Int Soc Oncodev Biol Med. 2013;34:1919–23.CrossRefGoogle Scholar
  11. 11.
    Xu Y, Liu L, Liu J, Zhang Y, Zhu J, Chen J, et al. A potentially functional polymorphism in the promoter region of mir-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer J Int Cancer. 2011;128:412–7.CrossRefGoogle Scholar
  12. 12.
    Tian Q, Jia J, Ling S, Liu Y, Yang S, Shao Z. A causal role for circulating mir-34b in osteosarcoma. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2014;40:67–72.Google Scholar
  13. 13.
    Gao LB, Li LJ, Pan XM, Li ZH, Liang WB, Bai P, et al. A genetic variant in the promoter region of mir-34b/c is associated with a reduced risk of colorectal cancer. Biol Chem. 2013;394:415–20.PubMedCrossRefGoogle Scholar
  14. 14.
    Yin J, Wang X, Zheng L, Shi Y, Wang L, Shao A, et al. Hsa-mir-34b/c rs4938723 t>c and hsa-mir-423 rs6505162 c>a polymorphisms are associated with the risk of esophageal cancer in a Chinese population. PLoS One. 2013;8:e80570.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Son MS, Jang MJ, Jeon YJ, Kim WH, Kwon CI, Ko KH, et al. Promoter polymorphisms of pri-mir-34b/c are associated with hepatocellular carcinoma. Gene. 2013;524:156–60.PubMedCrossRefGoogle Scholar
  16. 16.
    Zhang J, Huang X, Xiao J, Yang Y, Zhou Y, Wang X, et al. Pri-mir-124 rs531564 and pri-mir-34b/c rs4938723 polymorphisms are associated with decreased risk of esophageal squamous cell carcinoma in Chinese populations. PLoS One. 2014;9:e100055.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Zhang S, Qian J, Cao Q, Li P, Wang M, Wang J, et al. A potentially functional polymorphism in the promoter region of mir-34b/c is associated with renal cell cancer risk in a Chinese population. Mutagenesis. 2014;29:149–54.PubMedCrossRefGoogle Scholar
  18. 18.
    Hermeking H. The mir-34 family in cancer and apoptosis. Cell Death Differ. 2010;17:193–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, et al. P53-mediated activation of mirna34 candidate tumor-suppressor genes. Curr Biol CB. 2007;17:1298–307.CrossRefGoogle Scholar
  20. 20.
    Han Y, Pu R, Han X, Zhao J, Zhang Y, Zhang Q, et al. Associations of pri-mir-34b/c and pre-mir-196a2 polymorphisms and their multiplicative interactions with hepatitis b virus mutations with hepatocellular carcinoma risk. PLoS One. 2013;8:e58564.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Oh J, Kim JW, Lee BE, Jang MJ, Chong SY, Park PW, et al. Polymorphisms of the pri-mir-34b/c promoter and tp53 codon 72 are associated with risk of colorectal cancer. Oncol Rep. 2014;31:995–1002.PubMedGoogle Scholar
  22. 22.
    Bensen JT, Tse CK, Nyante SJ, Barnholtz-Sloan JS, Cole SR, Millikan RC. Association of germline microrna snps in pre-mirna flanking region and breast cancer risk and survival: the Carolina breast cancer study. Cancer Causes Control CCC. 2013;24:1099–109.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Jamroziak K, Szemraj J, Rawstron A, Szemraj-Rogucka Z, Grzybowska-Izydorczyk O, Giannopoulos K, et al. Polymorphisms of mir-34b/c, mir-146a and mir-196a-2 and predisposition to chronic lymphocytic leukemia and monoclonal b-cell lymphocytosis. Blood. 2011;118:4585.Google Scholar
  24. 24.
    Rozan LM, El-Deiry WS. P53 downstream target genes and tumor suppression: a classical view in evolution. Cell Death Differ. 2007;14:3–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Hollstein M, Sidransky D, Vogelstein B. CC H: P53 mutations in human cancers. Science. 1991;253:49–53.PubMedCrossRefGoogle Scholar
  26. 26.
    He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microrna component of the p53 tumour suppressor network. Nature. 2007;447:1130–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Vogt M, Munding J, Gruner M, Liffers ST, Verdoodt B, Hauk J, et al. Frequent concomitant inactivation of mir-34a and mir-34b/c by cpg methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch Int J Pathol. 2011;458:313–22.CrossRefGoogle Scholar
  28. 28.
    Deng G, Kakar S, Kim YS. Microrna-124a and microrna-34b/c are frequently methylated in all histological types of colorectal cancer and polyps, and in the adjacent normal mucosa. Oncol Lett. 2011;2:175–80.PubMedCentralPubMedGoogle Scholar
  29. 29.
    Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y, et al. Epigenetic silencing of microrna-34b/c and b-cell translocation gene 4 is associated with cpg island methylation in colorectal cancer. Cancer Res. 2008;68:4123–32.PubMedCrossRefGoogle Scholar
  30. 30.
    Suzuki R, Yamamoto E, Nojima M, Maruyama R, Yamano HO, Yoshikawa K, et al. Aberrant methylation of microrna-34b/c is a predictive marker of metachronous gastric cancer risk. J Gastroenterol. 2014;49:1135–44.Google Scholar
  31. 31.
    Muraoka T, Soh J, Toyooka S, Aoe K, Fujimoto N, Hashida S, et al. The degree of microrna-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma. Lung Cancer. 2013;82:485–90.PubMedCrossRefGoogle Scholar
  32. 32.
    Wang LG, Ni Y, Su BH, Mu XR, Shen HC, Du JJ. Microrna-34b functions as a tumor suppressor and acts as a nodal point in the feedback loop with met. Int J Oncol. 2013;42:957–62.PubMedGoogle Scholar
  33. 33.
    Dong F. Lou D: microrna-34b/c suppresses uveal melanoma cell proliferation and migration through multiple targets. Mol Vis. 2012;18:537–46.PubMedCentralPubMedGoogle Scholar
  34. 34.
    Kubo T, Toyooka S, Tsukuda K, Sakaguchi M, Fukazawa T, Soh J, et al. Epigenetic silencing of microrna-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17:4965–74.CrossRefGoogle Scholar
  35. 35.
    Svoboda M, Sana J, Redova M, Navratil J, Palacova M, Fabian P, et al. Mir-34b is associated with clinical outcome in triple-negative breast cancer patients. Diagn Pathol. 2012;7:31.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Liu C, Cheng H, Shi S, Cui X, Yang J, Yu X, et al. Microrna 34b inhibits pancreatic cancer metastasis through repressing smad3. Curr Mol Med. 2013;13:467–78.PubMedCrossRefGoogle Scholar
  37. 37.
    Bartel DP. Micrornas: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.PubMedCrossRefGoogle Scholar
  38. 38.
    Bossard P, Zaret KS. Gata transcription factors as potentiators of gut endoderm differentiation. Development. 1998;125:4909–17.PubMedGoogle Scholar
  39. 39.
    Chou J, Provot S, Werb Z. Gata3 in development and cancer differentiation: cells gata have it! J Cell Physiol. 2010;222:42–9.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Liang T-J, Liu H-J, Zhao X-Q, Yu C-H, Li C-S. Lack of association of mir-34b/c polymorphism (rs4938723) with hepatocellular carcinoma: a meta-analysis. PLoS One. 2013;8:e68588.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Wang Z, Wu J, Zhang G, Cao Y, Jiang C, Ding Y. Associations of mir-499 and mir-34b/c polymorphisms with susceptibility to hepatocellular carcinoma: an evidence-based evaluation. Gastroenterol Res Pract. 2013;2013:719202.PubMedCentralPubMedGoogle Scholar
  42. 42.
    Sun Q, Gu H, Zeng Y, Xia Y, Wang Y, Jing Y, et al. Hsa-mir-27a genetic variant contributes to gastric cancer susceptibility through affecting mir-27a and target gene expression. Cancer Sci. 2010;101:2241–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Shi D, Li P, Ma L, Zhong D, Chu H, Yan F, et al. A genetic variant in pre-mir-27a is associated with a reduced renal cell cancer risk in a chinese population. PLoS One. 2012;7:e46566.PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Chen X, Hu H, Guan X, Xiong G, Wang Y, Wang K, et al. Cpg island methylation status of mirnas in esophageal squamous cell carcinoma. Int J Cancer. 2012;130:1607–13.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Xiaowei Li
    • 1
  • Liguang Wang
    • 1
  • Jianyu Yu
    • 2
  • Jun Xu
    • 2
  • Jiajun Du
    • 1
    • 2
  1. 1.Institute of Oncology, Shandong Provincial Hospital Affiliated to Shandong UniversityShandong UniversityJinanPeople’s Republic of China
  2. 2.Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong UniversityShandong UniversityJinanPeople’s Republic of China

Personalised recommendations